Advertisement
Table 1 Characteristics of the whole and propensity score-matched cohorts of patients with locoregionally advanced nasopharyngeal carcinoma
| Characteristic | Whole cohort [cases (%)] | Propensity score-matched cohort [cases (%)] | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Cisplatin group | Docetaxel group | P value | Total | Cisplatin group | Docetaxel group | P value | |
| Total | 962 | 737 | 225 | 448 | 224 | 224 | ||
| Age | 0.245 | 0.124 | ||||||
| ≤ 50 years | 663 (68.9) | 515 (69.9) | 148 (65.8) | 311 (69.4) | 163 (72.8) | 148 (66.1) | ||
| > 50 years | 299 (31.1) | 222 (30.1) | 77 (34.2) | 137 (30.6) | 61 (27.2) | 76 (33.9) | ||
| Sex | 0.428 | 0.912 | ||||||
| Male | 716 (74.4) | 544 (73.8) | 172 (76.4) | 341 (76.1) | 170 (75.9) | 171 (76.3) | ||
| Female | 246 (25.6) | 193 (26.2) | 53 (23.6) | 107 (23.9) | 54 (24.1) | 53 (23.7) | ||
| Histological type (WHO) | ||||||||
| I | 4 (0.4) | 3 (0.3) | 1 (0.4) | 0.939 | 2 (0.4) | 1 (0.4) | 1 (0.4) | 1.000 |
| II–III | 958 (99.6) | 734 (99.7) | 224 (99.6) | 446 (99.6) | 223 (99.6) | 223 (99.6) | ||
| Clinical T stagea | 0.337 | 0.278 | ||||||
| T1–T2 | 226 (23.5) | 171 (23.2) | 55 (24.4) | 114 (25.4) | 59 (26.3) | 55 (24.6) | ||
| T3 | 591 (61.4) | 461 (62.6) | 130 (57.8) | 268 (59.9) | 138 (61.6) | 130 (58.0) | ||
| T4 | 145 (15.1) | 105 (14.2) | 40 (17.8) | 66 (14.7) | 27 (12.1) | 39 (17.4) | ||
| Clinical N stagea | 0.049 | 0.959 | ||||||
| N0 | 91 (9.5) | 72 (9.8) | 19 (8.4) | 40 (8.9) | 21 (9.4) | 19 (8.5) | ||
| N1 | 524 (54.5) | 398 (54.0) | 126 (56.3) | 252 (56.3) | 126 (56.3) | 126 (56.3) | ||
| N2 | 297 (30.8) | 221 (30.0) | 76 (33.8) | 151 (33.7) | 75 (33.5) | 76 (33.9) | ||
| N3 | 50 (5.2) | 46 (6.2) | 4 (1.8) | 5 (1.1) | 2 (0.9) | 3 (1.3) | ||
| Clinical stagea | 0.109 | 0.189 | ||||||
| II | 123 (12.8) | 85 (11.5) | 38 (16.9) | 80 (17.9) | 42 (10.2) | 38 (17.0) | ||
| III | 645 (67.0) | 501 (68.0) | 144 (64.0) | 298 (66.5) | 154 (68.8) | 144 (64.3) | ||
| IV | 194 (20.2) | 151 (20.5) | 43 (19.1) | 70 (15.6) | 28 (12.5) | 42 (18.7) | ||
| Pretreatment EBV DNA | 0.258 | 0.694 | ||||||
| < 4000 copies/mL | 633 (65.8) | 492 (66.8) | 141 (62.7) | 286 (63.8) | 145 (64.7) | 141 (62.9) | ||
| ≥ 4000 copies/mL | 329 (34.2) | 245 (33.2) | 84 (37.3) | 162 (36.2) | 79 (35.3) | 83 (37.1) | ||
